


Risk Awareness Dialogue Aid for Healthcare Professionals to Counsel Patients and Carers on the Potential for Inadvertent Use of an Empty Salbutamol pMDI

The **purpose of this material is for HCPs to reinforce the appropriate use of Salbutamol pMDI** when counseling patients and carers.

Please convey the key instructions below thoroughly:



Additional Information

How to access the website:

- Detailed information on this drug is available on GSKpro AZ | Prescribing Information for Healthcare Professionals.

In accordance with the requirements of the Resolution of the Cabinet of Ministers of the Republic of Azerbaijan “**Regulations of the pharmacovigilance of medicinal products**” dated 15 December 2019 and Resolution № 39, 25.08.2020 on approval of the “**Guidelines for Good Pharmacovigilance Practice**” approved by the Azerbaijan Republic Ministry of Health Analytical Expertise Center Pharmacovigilance sector all suspected adverse reactions should be reported to the cioms@pharma.az

How to report adverse reactions:

- In addition, regarding the occurrence of adverse reactions after administration of the drug, please report to GlaxoSmithKline Export Limited by e-mail: pm.safety@gsk.com